Get started
Author

Ningshu Liu

CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells
2003 · Ningshu Liu, Noriko Ohnishi, et al. · Nature Immunology · 294
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
2013 · Ningshu Liu, Bruce R. Rowley, et al. · Molecular Cancer Therapeutics · 266
Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS–ERK Signaling
2014 · Marie Will, Alice Can Ran Qin, et al. · Cancer Discovery · 197
Cell Cycle Regulation of E2F Site Occupation in Vivo
1996 · Jörk Zwicker, Ningshu Liu, et al. · Science · 152
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT
2017 · Juliane Paul, Maurice Soujon, et al. · Cancer Cell · 150
Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)
2016 · William J. Scott, Martin F. Hentemann, et al. · ChemMedChem · 126
PDF
A New Phospholipase C δ4 Is Induced at S-phase of the Cell Cycle and Appears in the Nucleus
1996 · Ningshu Liu, Kiyoko Fukami, et al. · Journal of Biological Chemistry · 123
PDF
Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment
2022 · Zhi Qi, Zihan Xu, et al. · Nature Communications · 114
PDF
A new model of cell cycle-regulated transcription: repression of the cyclin A promoter by CDF-1 and anti-repression by E2F
1998 · Ningshu Liu, Frances C Lucibello, et al. · Oncogene · 73
RETRACTED ARTICLE: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
2017 · Richard Hill, Patricia A. Madureira, et al. · Nature Communications · 69
PDF
BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models
2016 · Oliver Politz, Franziska Siegel, et al. · International Journal of Cancer · 61
PDF
Efficacy of phosphatidylinositol‐3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells
2015 · Elisa Göckeritz, Susan Kerwien, et al. · International Journal of Cancer · 44
PDF
Acetyl-CoA carboxylase inhibitors attenuate WNT and Hedgehog signaling and suppress pancreatic tumor growth
2016 · Elissaveta Petrova, Arne Scholz, et al. · Oncotarget · 42
PDF
T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1
2018 · Haichuan Zhu, Liuzhen Zhang, et al. · eLife · 38
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
2020 · Chiara Tarantelli, Martin Lange, et al. · Blood Advances · 36
PDF
Evaluation of the PIK3 pathway in peripheral T‐cell lymphoma and NK/T‐cell lymphoma
2020 · Dachuan Huang, Tammy Linlin Song, et al. · British Journal of Haematology · 36
PDF
Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses
2023 · Simon Heller, Sarah Glaeske, et al. · Clinical and Experimental Medicine · 30
PDF
The novel PI3 kinase inhibitor, BAY 80‐6946, impairs melanoma growth in vivo and in vitro
2014 · Philine Schneider, Margarete Schön, et al. · Experimental Dermatology · 15
Doxorubicin‐induced activation of NF‐κB in melanoma cells is abrogated by inhibition of IKKβ, but not by a novel IKKα inhibitor
2012 · Nadin Pletz, Margarete Schön, et al. · Experimental Dermatology · 15
PDF
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
2024 · Ruicheng Wei, Wenli Zhang, et al. · Journal of Translational Medicine · 10
Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439
2018 · Yongkang Zou, Zhi Qi, et al. · Molecular Cancer Therapeutics · 8
Abstract LB-123: Pulsatile inhibition of PI3K converts immune suppression by Tregs and M2-TAM to anti-tumor immune response in animal models insensitive or resistant to the monotherapies of PI3K and checkpoint inhibitors
2018 · Sarah Glaeske, Franziska Huebner, et al. · Cancer Research · 4
Abstract 154: The phosphatidylinositol-3-kinase (PI3K) inhibitor (i) copanlisib is active in preclinical models of B-cell lymphomas as single agent and in combination with conventional and targeted agents including venetoclax and palbociclib
2017 · Eugenio Gaudio, Ivo Kwee, et al. · Cancer Research · 3
Abstract 379: Allosteric AKT1/2-inhibitor BAY 1125976 as potent inhibitor in luminal breast cancer resistant to antihormone therapy
2016 · Oliver Politz, Lars Baerfacker, et al. · Cancer Research · 3
Abstract 4476: BAY 80-6946, a highly selective and potent pan class I PI3K inhibitor induces tumor apoptosis in vitro and tumor regression in vivo in a sub-set of tumor models
2010 · Ningshu Liu, Bruce Rowley, et al. · Cancer Research · 3
Works count: 80
Citation count: 1,925
H-index: 17
I10-index: 20
Year
Topic
Type